

NEWSLETTER

Volume 4, No. 2

Message from the IFHRS Chair

Wilma F. Bergfeld, MD, IFHRS Chair, BERGFEW@ccf.org



HAPPY HOLIDAYS TO ALL THE IFHRS MEMBER SOCIETIES!

I was so pleased to see all of you at the Zoom meeting on December 1, 2023. We are well organized, well funded, engaged, and prepared to move forward with the 2030 Open Hub bid. Many thanks to Gill Westgate's leadership and the Open Hub Task Force for all their efforts and the final approved application. As you reflect, a timeline for the Open Hub application has been established and the selection method decided upon. I'd also like to thank Yuliya Ovcharenko. She and her task force developed an IFHRS website that is beyond imagination in creativity and so complete. It will serve us well now and in the future.

The IFHRS's major efforts have focused on the World Congresses of Hair Research, for which an international rotation has been created, with an application and selection process. This effort includes garnering participation by all society members to support the congresses, to support the travel grants, and to encourage young clinicians and researchers to participate as we fulfill our mission to share knowledge and experiences that support and advance the care of hair loss patients.


Our next congress—WCHR2024—will be held April 6-9, 2024, in Dallas, Texas, during the total solar eclipse. Angela Christiano, Scientific Co-Chair, presented an exciting program and outlined the wonderful congress events at our December 1, 2023, IFHRS Board Meeting. Thus far, there has been a large volume of submitted abstracts, posters, and exhibits. Registration has opened and we encourage you to register early to secure your hotel room. To register, go to www.hair2024.org.

Thank you for participating in the quarterly *IFHRS Newsletter*. It has become an important communication vehicle for us as our individual societies span the globe. Please enjoy the newsletter and be sure to send in your society's meetings calendar, including upcoming events and announcements, as well as noteworthy achievements of any of your members you'd like to share.

I look forward to seeing you all in Dallas, Texas, for the WCHR2024 meeting!



REGISTRATION IS OPEN:
www.hair2024.org



IFHRS

International Federation
of Hair Research Societies

In This Issue

American Hair Research Society	2-3
Australasian Hair and Wool Research Society	4-6
Chinese Hair Research Society	7-9
European Hair Research Society	10-11
The Korean Hair Research Society	12-14
Russian Hair Research Society	15-16
The Society for Hair Science Research (Japan)	17-18
Ukrainian Hair Research Society	19-20

Angela M. Christiano, PhD, AHRS President | amc65@columbia.edu | www.americanhairresearchsociety.org

2024 WORLD CONGRESS OF HAIR RESEARCH

Planning for the World Congress of Hair Research (www.hair2024.org) is well underway and the meeting is just about 100 days away! We had an extraordinary response to the Abstract Deadline in September, with submissions from 27 countries around the world. The meeting will feature pre-meeting symposia and workshops, keynote lectures, plenary sessions, live patient viewing, concurrent sessions, sponsored symposia and a dynamic and exciting social program. One theme of the meeting is the promotion of interactions between basic science and clinical colleagues, with new sessions such as Methods Matchmaking. The highlight of the meeting is the viewing of the total solar eclipse on Monday, April 8, 2024, since Dallas, Texas, is in the path of totality. Don't miss this opportunity to participate in the World Congress of Hair Research and experience the total eclipse, which will not be visible in North America for another 20 years! Stay tuned for Late-Breaking Abstract submissions to open in January 2024.



2023 WEBINAR

The AHRS offered a webinar on December 2, 2023, entitled “The Use of Mesotherapy for Hair Loss.” Drs. Neil Sadick and Antonella Tosti organized this webinar, which was attended by more than 100 people. Mesotherapy involves the direct injection of bioactive compounds into the scalp for the treatment of hair loss. Topics covered in the webinar included an overview of mesotherapy (Dr. Neil Sadick), treatment protocols for treatment for hair loss (Dr. Suleima Arruda), MMP technology (Dr. Mariana Lima), safety considerations and side effects (Drs. Antonella Tosti and Leonardo Spagnol Abraham). Concluding this webinar, there was a moderated panel discussion among the faculty on the various protocols and considerations for using mesotherapy in the treatment of hair loss. Panelists included Drs. Neil Sadick, Antonella Tosti, Sergio Vañó Galván, Leonardo Spagnol Abraham, and Suleima Arruda.

2024 UPCOMING EVENTS

The AHRS will be holding two webinars in 2024, currently slotted for June 1, 2024, and November 9, 2024. The topics are being developed. Our online programming has been a popular feature for our members, and we plan to continue hosting educational content in this dynamic and accessible format.

The AHRS will host its annual Scientific Session & Luncheon at the American Academy of Dermatology Annual Meeting coming up on Friday March 8, 2024, in San Diego. The scientific program will focus on presentations of the AAD HAIR Grants that were first introduced at the AHRS Luncheon two years ago. Lectures include Investigating the Impact of Hair Washing on Scalp Cytokine

March 8, 2024 – AHRS Meeting at AAD Annual Meeting

April 6-9, 2024 – 13th World Congress for Hair Research

May 8-11, 2024 – RADLA / AHRS Session

May 17, 2024 – AHRS Meeting at SID Annual Meeting

June 2024 – AHRS Webinar

November 19-23, 2024 – CILAD / AHRS Session


December 2024 – AHRS Webinar

(Continued next page)

Expression in Patients with CCCA (Dr. Crystal Aguh), Mast Cells in CCCA (Dr. Lynne Goldberg), Identification of Biomarkers for CCCA (Dr. John Seykora), and Establishment of a Preclinical Model for Human PCA Using the Asebia Mouse (Dr. Angela Christiano). In addition, there will be a presentation of the AHRS Mentorship Awards to this year's recipients, as well as updates from the National Alopecia Areata Foundation (NAAF) by Nicole Friedland, President & CEO of NAAF, and the Scarring Alopecia Foundation (SAF) by Jean Pickford, Executive Director of SAF. Please join us for this exciting program!

The AHRS is looking forward to additional educational and scientific programs in the first half of 2024. In addition to the AAD Luncheon in March and the World Congress of Hair Research in April, the AHRS will return to hosting a scientific session at the Society for Investigative Dermatology (SID) Annual Meeting on Friday evening May 17, 2024, and a session at the upcoming RADLA meeting to be held in Lima, Peru, May 8-11, 2024. Finally, the National Alopecia Areata Foundation Annual Patient Conference will take place on June 27-30, 2024, where several AHRS members will speak and participate in panel discussions within NAAF's annual meeting.

WCHR24 PROGRAM-AT-A-GLANCE

SATURDAY • APRIL 6					SUNDAY • APRIL 7				MONDAY • APRIL 8					TUESDAY • APRIL 9			
PAVILION ROOM	PARISIAN ROOM	GOLD ROOM	INTERNATIONAL BALLROOM	REGENCY BALLROOM & FOYER	INTERNATIONAL BALLROOM	VENETIAN ROOM	GOLD ROOM	REGENCY BALLROOM & FOYER	POOL TERRACE & PAVILION ROOM	INTERNATIONAL BALLROOM	VENETIAN ROOM	GOLD ROOM	REGENCY BALLROOM & FOYER	INTERNATIONAL BALLROOM	VENETIAN ROOM	GOLD ROOM	
6:30AM																6:30AM	
7:00AM					SATELLITE SYMP 1 with Breakfast					SATELLITE SYMP 4 with Breakfast				SATELLITE SYMP 6 with Breakfast		7:00AM	
7:30AM																7:30AM	
8:00AM													Exhibits and Posters	Coffee with the Experts		8:00AM	
8:30AM					SESSION 3 Plenary - Cutting Edge Hair Research Technologies			Exhibits and Posters		SESSION 13 Plenary Topic				SESSION 24 Plenary Session		8:30AM	
9:00AM																9:00AM	
9:30AM					SESSION 4 Keynote					SESSION 14 Solar Eclipse/ Space Keynote				SESSION 25 Keynote (Ebling Lecture)		9:30AM	
10:00AM					Coffee Break EXHIBIT HALL		Live Patient Viewing			Coffee Break & Formal Poster Session (Evens)						10:00AM	
10:30AM					SESSION 5 Male Pattern Hair Loss	SESSION 6 Hair Follicle Stem Cells				SESSION 15 Scarring Alopecia	SESSION 16 Hair Follicle Morphogenesis and Dermal Papilla	SESSION 17 Hair Care and Aesthetics		SESSION 26 Biology and Biophysics of Textured Hair	SESSION 27 Pediatric Hair Loss and Genodermatoses	SESSION 28 Hair Follicle Metabolism & Micronutrients	10:30AM
11:00AM																	11:00AM
11:30AM																	11:30AM
12:00AM																	12:00AM
12:30AM					SATELLITE SYMP 2 with Lunch Sponsored by LILLY				 TOTAL SOLAR ECLIPSE with Lunch BEGINS 12:23 MAX AT 1:43 ENDS 3:02				SESSION 29 JAK Inhibitors in the Treatment of Hair Loss	SESSION 30 Psychosocial Burden of Hair Disorders & Outcome Measures	SESSION 31 Natural Products & Botanical Preparations for Hair Disorders	12:30AM	
1:00PM	PRE-CONGRESS WORKSHOP 101 Basics of Mouse Hair Follicle Biology	PRE-CONGRESS WORKSHOP 102 Management of Hair Patients: Clinical Pearls and Practical Approaches	PRE-CONGRESS SYMP 103 Translational Research	Exhibit Hall and Poster Set Up													1:00PM
1:30PM																	1:30PM
2:00PM					SESSION 7 Alopecia Areata and Immunobiology	SESSION 8 Imaging and Trichoscopy Advances	SESSION 9 Live Patient Viewing Discussion & Devices (Trichoscopy)			SESSION 18 Regenerative Medicine and Biologic Therapies	SESSION 19 Female Hair Loss, Hormones, and Aging	SESSION 20 Hair Follicle Micro-environment		SESSION 32 Closing Ceremony & Brunch			2:00PM
2:30PM																	2:30PM
3:00PM	PRE-CONGRESS WORKSHOP 104 The Who, What, Where and Why of Trichology																3:00PM
3:30PM					Coffee Break EXHIBIT HALL					Coffee Break & Formal Poster Session (Odds)							3:30PM
4:00PM					SESSION 10 Hair Restoration Surgery	SESSION 11 Great Cases from Around the World	SESSION 12 Single Cell Analysis of the Hair Follicle			SESSION 21 Photobiomodulation and Lasers	SESSION 22 Hair Follicle Pigmentation, Cycling, and Senescence	SESSION 23 Hair Care in Transgender Patients					4:00PM
4:30PM																	4:30PM
5:00PM					Exhibits and Posters								Exhibit Hall & Poster Tear Down				5:00PM
5:30PM				SESSION 1 Opening Ceremony and Plenary Topic		Curbside Consults	Methods Matchmaking										5:30PM
6:00PM				SESSION 2 Keynote Speaker Topic	SATELLITE SYMP 3 Happy Hour Sponsored by L'OREAL						SATELLITE SYMP 5 Happy Hour						6:00PM
6:30PM																	6:30PM
7:00PM					WELCOME RECEPTION EXHIBIT HALL 7:00-8:30PM		FACULTY DINNER OFFSITE 7:00-9:00PM			CONGRESS DINNER OFFSITE Gilley's Dallas 7:00-10:00PM							7:00PM
7:30PM																	7:30PM
8:00PM																	8:00PM

12/12/23

12/12/23



Australasian Hair and Wool Research Society

Rod Sinclair, MBBS, MD, AHWRS President | rodney.sinclair@sinclairdermatology.com.au | <http://ahwrs.org.au/>

Leslie Jones, PhD, AHWRS Secretary

HAIR FELLOWS AT AHWRS

The AHWRS provides scholarships to enable locally and internationally qualified specialist dermatologists to undertake a 12-month clinical fellowship in diseases of the hair and scalp. It is ideal for dermatologists who want to develop subspecialty expertise in the area. Fellows are exposed to patients with alopecia areata, male and female pattern hair loss, cicatricial alopecia, and congenital hair disorders. Fellows have the opportunity to consult with approximately 100 hair patients per week and to build significant clinical experience. This is ideal preparation for dermatologists wanting a career in the treatment of patients with hair disease. Fellows have access to biologics, Janus kinase inhibitors, and a range of advanced therapeutics.

Current Fellows

Dr. Daranporn (Tone) Triwongwanarat

Tone commenced her 12-month hair fellowship in Australia at Sinclair Dermatology in December 2022. She was enjoying it so much, she chose to extend it for an additional 12 months and will stay until December 2024. Prior to coming to Australia, Tone was a clinical instructor at the Department of Dermatology the faculty of Medicine Siriraj Hospital Mahidol University, Thailand. She previously completed a Dermatology residency training in 2014



Current fellows (l to r): Drs. Daranporn Triwongwanarat, Daniela Kushnir Grinbaun, and Yong Shin Shen

and a Fellowship in hair disorder and hair transplantation in 2015 from Siriraj Hospital, Mahidol University, Thailand. Tone has had an opportunity to learn about Janus kinase inhibitor treatment for alopecia areata and minoxidil treatment for male and female pattern hair loss, and she has also been an associate investigator in a number of sponsored clinical trials.

Dr. John Frewen – Ireland

John commenced his fellowship in October 2023 and has already participated in a number of research projects and publications. He is involved in alopecia areata and androgenetic alopecia clinical trials. Having completed his undergraduate medical degree at Trinity College Dublin, John completed his specialist dermatology training in the South of England at the Royal Cornwall Hospital (2019–2021) and at the Royal Devon and Exeter Hospital (2021–2023).

Dr. Daniela Kushnir Grinbaun – Israel

Daniella completed her specialist training in Dermatology at the Emek Medical Centre in Israel in 2023. She has a long-standing interest in hair disorders and will commence her fellowship in 2024.


Dr. Yong Shin Shen – Singapore

Sean is a consultant dermatologist and physician at the University of Malaya's Dermatology Unit. He has a long-standing interest in hair and nail disorders, and he has arranged a sabbatical post to Australia to further his interest in the area. We look forward to welcoming Sean in 2024.

(Continued next page)

72ND LINDAU NOBEL LAUREATE MEETING | GERMANY

This year, the Lindau Nobel Laureate Meeting, which was dedicated to Physiology/Medicine, was held in Lindau, Lake Constance, Germany, from 25-30 June, 2023. During this event, select young scientists representing their countries have the chance to meet the Nobel prize winners and to build their network of young scientists around the globe. This year, approximately 600 undergraduates, PhD students, and post-doctoral researchers met 39 Nobel prize winners during several scientific programs, such as Agora Talk, Open Exchange, Lectures, Science Walk, and Panel Discussion. To attend this exclusive event, these young scientists had to pass a competitive, multi-stage application and nomination process, which was first done by the nominating countries and then done by the Lindau Nobel Laureate Meeting Committee. Agnes Rosarina Prita Sari (Ita) was one of the young scientists invited for this year's event. She received her Masters and PhD degrees in Faculty of Medicine, Dentistry, and Health Sciences from the University of Melbourne, under the supervision of Prof. Rodney Sinclair. Her research interest is mainly concerning human hair follicle.



Christiane Nusslein-Volhard during her lecture at 72nd Lindau Nobel Laureate Meeting. She received the Nobel Prize in Physiology or Medicine in 1995 for the discoveries concerning the genetic control of early embryonic development.



Ita with Sir Martin J. Evans who received Nobel Prize in Physiology or Medicine in 2007 for research on embryonic stem cells and the switching off of individual genetic information in mammals.



Ita with Emmanuelle Charpentier who received Nobel Prize in Chemistry in 2020 for the development of a method for genome editing (CRISPR-Cas9).

PUBLISHED RESEARCH

While Members of the AHWRS have been hard at work in the clinic over the past 6 months, they have also been productive on the research front and produced a number of collaborative, local and international, multiauthor publications.

Research fellow Dr. Ashling Courtney recently reviewed 5-alpha-reductase type II inhibitors (5ARIs) for the treatment of male androgenetic alopecia (AGA).¹ This paper reminds the reader that the initial pathogenesis of AGA involves progressive shortening of anagen duration. This manifests initially as telogen effluvium. Subsequent hair follicle miniaturization leads to reduced hair fibre diameter. These two events combine to produce visible baldness. 5ARIs do not prolong anagen duration and do not reduce hair shedding but potentially arrest miniaturization and halt the progression of baldness. Finasteride and dutasteride may also induce partial hair regrowth over the vertex scalp. A lesser degree of hair growth may occur over the mid-frontal scalp, but regrowth of bitemporal recession is rare.

Research fellow Dr. Toan Tang recently published a systematic review on the effect of gender-affirming hormone therapy (GAHT) and effects on hair growth.² The impact of GAHT on hair growth may not align with a transgender person's hair growth goals and specific treatment for AGA and/or hirsutism may be sought. Dr. Tang is currently embarking on a study to monitor changes in scalp and facial hair growth with GAHT.

Dr. Anneliese Willems reported on the prescribing behaviour of Australian dermatologists in androgenetic alopecia.³ Survey responses were received from just over 10% of all Australian dermatologists. The most common treatments for male pattern hair loss were oral finasteride (35%), followed by oral minoxidil (28%), topical minoxidil (26%), sublingual minoxidil (7%), and oral dutasteride (4%). Oral finasteride and systemic minoxidil (SM – oral and sublingual) were equally prescribed as the most common treatments for AGA. In this, our findings demonstrate that SM is frequently prescribed off-label in Australia, reflecting a shift towards the increasing use of SM for AGA.

(Continued next page)

Dr. Samantha Eisman and Rod Sinclair described the incidence and point prevalence of alopecia areata (AA) in Australia through analysis of an Australian primary healthcare patient population database.⁴ The findings were consistent with earlier estimates from other countries. The incidence of new-onset AA in the total study cohort was 0.278 per 1,000 person-years (95% CI 0.26-0.295). AA point prevalence at 31/12/2020 was 0.13% (1.26 per 1,000 persons; 95% CI 1.15-1.37).

Dr. Huw Rees et al looked at the reliability and validity of a measure to assess the health-related quality of life of women with alopecia areata.⁵ The Women's Androgenetic Alopecia Quality of Life (WAA-QoL) questionnaire is a reliable, validated HRQoL measure in women with androgenetic alopecia (AGA). There is no equivalent measure for female patients with AA. Overall, 137 individuals completed questionnaires. There was excellent internal consistency of the WAA-QoL among women with AA (Cronbach's $\alpha = 0.98$). A moderate and high positive correlation was found between the WAA-QoL and the DLQI and the Skindex-16 for AA, respectively. Data were collected as part of the Global Registry of Alopecia Areata Disease Severity and Treatment Safety (GRASS) Australia, which is supported by Pfizer.

Prof. Rod Sinclair published on a novel monoclonal antibody cream.⁶ In this instance, it was used to treat psoriasis, but the technology has potential application for all skin disease including alopecia areata.

Dr. Leila Asfour published on the unmet need of male patients with alopecia areata and also on the treatment of pre-adolescent children with JAKi.^{7,8}

Members of the AHWRS collaborated in important international studies on alopecia areata and chronic telogen effluvium.⁹⁻¹⁴

References

1. Courtney A, Triwongwarant D, Chim I, Eisman S, Sinclair R. Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia. *Expert Opin Pharmacother*. 2023 Nov 9;1-4. Online ahead of print.
2. Tang GT, Zwickl S, Sinclair R, Zajac JD, Cheung AS. The effect of gender-affirming hormone therapy on hair growth: A systematic review of the literature. *Clin Exp Dermatol*. 2023 Jun 13;ljad203.
3. Willems A, Moussa A, Sinclair R. Australian dermatologists' prescribing behaviours for male androgenetic alopecia. *Australas J Dermatol*. 2023 Aug;64(3):429-432. Epub 2023 Jun 13.
4. Sinclair R, Eisman S, Song W, Heung B, Surian C, Lee CM, Witcombe D. Incidence and prevalence of alopecia areata in the Australian primary care setting: A retrospective analysis of electronic health record data. *Australas J Dermatol*. 2023 Aug;64(3):330-338. Epub 2023 Jul 6.
5. Rees H, Wall D, Bokhari L, Asfour L, Sinclair R. The reliability and validity of a measure to assess the health-related quality of life of female alopecia areata patients. *Clin Exp Dermatol*. 2023 48 (6), 681-684.
6. Sinclair R, Sharifeh S, Thackwray S, Lickliter J, Wu J, Li J, Qi B, Bland-Ward P, Reinhart H. Topical application of a novel anti-interleukin-17A antibody fragment penetrates psoriatic skin: Results of a randomised, double-blind, placebo-controlled Phase Ib study. *Exp Dermatol*. 2023 Sep;32(9):1538-1545. Epub 2023 Jun 28.
7. Asfour L, Bokhari L, Bhoyrul B, Eisman S, Moussa A, Rees H, Sinclair RD. Treatment of moderate-to-severe alopecia areata in pre-adolescent children with baricitinib. *Br J Dermatol*. 2023 Jul 17;189(2):248-250.
8. Asfour L, Bokhari L, Bhoyrul B, Eisman S, Moussa A, Rees H, Sinclair RD. Comment on "Treatment of moderate-to-severe alopecia areata in pre-adolescent children with baricitinib-Response letter": reply from authors. *Br J Dermatol*. 2023 Aug 19;ljad276.
9. King B, Mostaghimi A, Shimomura Y, Zlotogorski A, Choi GS, Blume-Peytavi U, Passeron T, Holzwarth K, Dutronc Y, McCollam J, Yang FE. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials. *Br J Dermatol*. 2023 Feb 10;188(2):218-227.
10. King B, Mirmirani P, Lo Sicco K, Ramot Y, Sinclair R, Edwards R, Kerkmann U, Wajsbrot D, Zwillich S, Lejeune A. LB1697 Individual SALT score trajectories of de novo patients with alopecia areata (AA) treated with ritlecitinib in the ongoing phase 3, long-term, open-label ALLEGRO-LT study. *J Invest Dermatol*. 2023.
11. King B, Shapiro J, Ohyama M, Egeberg A, Piraccini BM, Craiglow B, Sinclair R, Chen YF, Wu WS, Ding Y, Somani N. When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials. *Br J Dermatol*. 2023 Sep 14;ljad253.
12. Senna MM, Kwon O, Piraccini BM, Sinclair R, Ball S, Ding Y, Chen YF, Dutronc Y, King B. Clinical benefits of baricitinib therapy according to scalp hair regrowth in patients with severe alopecia areata. *Dermatol Ther (Heidelb)*. 2023 Nov 22;13(12):3209-20.
13. King B, Zhang X, Harcha WG, Szepletowski JC, Shapiro J, Lynde C, Mesinkovska NA, Zwillich SH, Napatalung L, Wajsbrot D, Fayyad R, Freyman A, Mitra D, Purohit V, Sinclair R, Wolk R. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial. *Lancet*. 2023;401:1518-1529.
14. Dauntan A, Harries M, Sinclair R, Paus R, Tosti A, Messenger A. Chronic telogen effluvium: Is it a distinct condition? A systematic review. *Am J Clin Dermatol*. 2023 Jul;24(4):513-520. Epub 2023 Apr 13.

Chinese Hair Research Society

Jianzhong Zhang, MD, CHRS Chairman | rmzjz@126.com

ACADEMIC ACTIVITIES IN 2023

The 7th Annual Meeting of Chinese Hair Research Society

The 7th Annual Meeting of Chinese Hair Research Society (CHRS) was successfully held August 25-27, 2023, in Chongqing, China. It was organized by CHRS and undertaken by the Second Affiliated Hospital of Chongqing Medical University. A total of 360 delegates from 26 provinces across China attended the meeting, and more than 50 international and domestic experts were invited to give their splendid lectures on basic hair research and the latest frontiers on the diagnosis and therapy of hair related diseases.

On August 26, Professor Jianzhong Zhang, the president of CHRS, delivered his speech on behalf of CHRS at the opening ceremony. He summarized the progress and development of CHRS in recent years and also expressed his expectation for the future. Over the course of the next two days of meetings, a total of 55 lectures were given, covering a wide range of topics from basic research to clinical diagnosis and treatment of hair diseases. There were several special sessions that included the topics of “Basic and Clinical Research,” “Private Hair Institutions in China,” and “Hair transplantation and Operation,” which significantly promoted the communication between the basic researchers and clinical dermatologists as well as the national and private hair institutions across China. During the meeting, CHRS also discussed the revised version of “Chinese Guidelines for the Diagnosis and Treatment of Androgenic Alopecia,” which was expected to be officially published in 2024.

The conference presented a splendid academic feast and received very high praise. It provided an opportunity for Chinese dermatologists to share their great ideas and experience. We believe more Chinese dermatologists and patients will benefit from this meeting in the future.

(Continued next page)



Opening ceremony and posters from the 7th Annual Meeting of CHRS.



Some of the speakers at the 7th Annual Meeting of CHRS.



Group photo from the 7th Annual Meeting of CHRS.

OTHER ACADEMIC ACTIVITIES IN 2023

The 5th Symposium for Updates of Hair Disorders and Cosmetic Dermatology | Peking University People's Hospital | December 1-3, 2023 | Beijing



Group photo from the 5th Symposium for Updates of Hair Disorders and Cosmetic Dermatology



The practical operation of trichoscopy in clinical trials received great attention from attendees the 5th Symposium for Updates of Hair Disorders and Cosmetic Dermatology.

Symposium for Dermatologic Surgery and New Advances on Hair Transplantation | Huashan Hospital, Fudan University | November 24-26, 2023 | Shanghai



Group photo from the Symposium for Dermatologic Surgery and New Advances on Hair Transplantation

Symposium for Pigmented and Hair Loss Diseases | Huashan Hospital, Fudan University | November 24-26, 2023 | Shanghai



Group photo from the Symposium for Pigmented and Hair Loss Diseases

(Continued next page)

The 6th West Lake Hair Conference | March 25-26, 2023



Group photo from the 6th West Lake Hair Conference

Additionally, there have been hold over 100 seminars and online forums on hair loss held throughout China this year.

THE MEDICAL CARE, RESEARCH, AND INDUSTRY FOR HAIR LOSS IS BOOMING IN CHINA

Hair health has been receiving increasing attention from patients, the public, and the media in recent years. More dermatologists are beginning to engage in hair medicine, and more companies are paying attention to the hair market. New drugs, medical equipment, and hair care products are emerging one after another. These are some of the latest news and updates on medicine development in China:

1. Baricitinib was approved to treat adult patients with severe alopecia areata (AA) by China National Medical Products Administration (NMPA) on March 27, 2023.
2. Ritlecitinib was approved to treat adults and adolescents with severe AA by China NMPA on October 19, 2023.
3. Many new drugs for treating hair loss are currently undergoing phase 2 or phase 3 clinical trials, such as topical KX-826 for AGA in males and females, topical finasteride for male AGA, HMI-115 for male AGA, et al.

UPCOMING ACTIVITIES IN 2024

The 8th Annual Meeting of the CHRS will be held August 23-25, 2024, in Yanji city, China. Yanji, a small city with ethnic Korean style and beautiful scenery, is located in the center of the Yanbian Korean Autonomous Prefecture in northeast China's Jilin Province. The summers are mild and cool, and the picturesque scenery will definitely make the attending representatives linger and forget to leave. The secretary of the meeting is Prof. Longquan Pi from Yanbian University Hospital, email: plq6833@163.com.



Yanji City, China



Heaven Pool



European Hair Research Society

Yuval Ramot, MD, MSc, EHRS Board Member;

Sergio Vañó Galván, MD, PhD, EHRS Secretary | secretary@ehrs.org | <https://ehrs.org/>

REINVIGORATED “WHAT’S NEW IN HAIR” SECTION

We are delighted to announce the revival of the esteemed “What’s New in Hair” section on the EHRS website. After a brief hiatus, we’re thrilled to reintroduce this valuable resource to our members. This section serves as a beacon for the latest advancements, insights, and discoveries in the field of hair research.

In November, our dedicated team proudly presented a fresh post, thoughtfully curated by Dr. Andrey Panteleyev. Dr. Panteleyev’s comprehensive review delves into recent and compelling articles that explore various aspects of hair research, providing a profound analysis and discussion of noteworthy findings.

This revitalized section promises to be an invaluable asset, offering members an exclusive opportunity to stay abreast of cutting-edge research and scientific discussions within our specialized domain. We encourage all members to explore this renewed feature on our website and take advantage of the wealth of knowledge it offers.

We extend our heartfelt gratitude to Dr. Panteleyev for his insightful contribution and commitment to advancing our understanding of hair research.

Stay tuned for further updates and enrich your knowledge with the “What’s New in Hair” section.

CELEBRATING EXCELLENCE: DR. CLAIRE HIGGINS, FIRST-PLACE RECIPIENT OF THE MARTHA SCHWARZKOPF AWARD FOR WOMEN IN SCIENCE

We are thrilled to announce that Dr. Claire Higgins, president of the European Hair Research Society, has clinched the prestigious first place in the Martha Schwarzkopf Award for Women in Science by Henkel, and this is a testament to her exceptional contributions to the field of hair research.

The Martha Schwarzkopf Award, initiated by Henkel to champion and recognize outstanding female scientists, serves as a beacon of support for women in various scientific domains. Dr. Higgins stands as the foremost among the three esteemed winners of this year’s award, celebrated for their remarkable accomplishments in hair research and related fields.

Dr. Higgins’s exemplary achievement of securing first place and the substantial prize of 10,000 euros is a testament to her dedication and remarkable contributions to the field. The European Hair Research Society extends heartfelt congratulations to Dr. Higgins on this outstanding accomplishment and remains committed to fostering a culture of excellence and inclusivity in scientific research.



DR. SERGIO VAÑÓ GALVÁN HONORED—SPAIN’S MOST REPUTABLE DERMATOLOGIST FOR 2023

We are thrilled to announce that our esteemed secretary, Dr. Sergio Vañó Galván, has been recognized as one of the most reputable physicians in Spain for the year 2023! This prestigious accolade, organized by Merco (Monitor of Corporate Reputation), the Observatory of Health, and the Health Reputation Monitor, signifies a remarkable achievement in Dr. Vañó Galván’s illustrious career.

The award selection process was based on the votes of 4,300 physicians and 100 executives from healthcare companies. Dr. Vañó Galván was awarded as the most reputable dermatologist in Spain in 2023. His exceptional contributions and ded-

(Continued next page)

ication to the hair research field resonated deeply among peers and industry leaders, leading to this well-deserved recognition.

The award ceremony, held at the prestigious Fundación Mutua Madrileña on November 13, 2023, was graced by the presence of prominent figures in the healthcare sector, including Dr. Fátima Matute, Madrid's Health Counselor, and Mr. José Manuel Miñones, the Minister of Health, among other dignitaries.

Dr. Vañó Galván's outstanding achievement not only reflects his expertise and commitment to excellence in the medical field, but it also serves as an inspiration to us all within the European Hair Research Society.

Congratulations, Dr. Sergio Vañó Galván, on this remarkable accomplishment!



REVIEW OF “SAFETY OF LOW-DOSE ORAL MINOXIDIL IN PATIENTS WITH HYPERTENSION AND ARRHYTHMIA”

A recent study conducted by Jimenez-Cauhe et al¹ delved into the safety aspects of using low-dose oral minoxidil (LDOM) for individuals diagnosed with hypertension. The investigation involved 264 patients from multiple centers across Brazil and Spain, aiming to assess the viability of LDOM as a treatment for hair loss in this particular patient demographic.

The findings of the study present encouraging results. LDOM exhibited a notably favorable safety profile among patients diagnosed with hypertension. Notably, the frequency of adverse effects linked to LDOM use and the rates of treatment discontinuation remained comparable to those observed in the general population.

One significant implication highlighted by the study is the potential for patients undergoing treatment for hypertension to commence LDOM without necessitating a prior referral to a cardiologist. The study authors propose management recommendations based on their findings, contributing valuable insights that may guide medical professionals in the effective and safe utilization of LDOM in patients with hypertension. The detailed findings and proposed management recommendations from this study provide important perspectives that could significantly impact the clinical approach to managing hair loss in patients diagnosed with hypertension.

Reference

1. Jimenez-Cauhe J, Pirmez R, Müller-Ramos P, et al. Safety of low-dose oral minoxidil in patients with hypertension and arrhythmia: a multicenter study of 264 patients. *Actas Dermosifiliogr*. 2023 Nov 3:S0001-7310(23)00867-0. PMID: 37923070.

The Korean Hair Research Society

Chang Hun Huh, MD, PhD, Secretary General/International Relationship Director of KHRS |
chhuh@snu.ac.kr | <http://www.khrs.or.kr/>

HOT TOPICS

Korean Guideline Committee for the Diagnosis of Severe Alopecia Areata

Because the definition of severe alopecia areata remains unclear, with the recent introduction of new drugs that are effective against severe alopecia areata, the Korean Hair Research Society (KHRS) has established a committee to develop diagnostic guidelines for severe alopecia areata in Korea. The committee created a questionnaire based on the latest evidence-based literature and developed diagnostic criteria for severe alopecia areata based on expert consensus, which will be published as a paper. The committee also created a questionnaire on the factors that determine severe alopecia areata in the opinion of patients and is planning to approach the definition of severe alopecia areata from multiple angles through a patient and patient-caregiver questionnaire.

Health Column Contribution of JoongAng Ilbo Health Media

The KHRS contributed to JoongAng Ilbo's Health Media Health Column on the topic, "The Key to Hair Loss Treatment as Told by Dermatologists." One article was published each month through November for a total of 10 articles. Our intent was to use these health column articles by medical staff from the KHRS to correct patients' misconceptions about hair loss and help them receive the right treatment.

2023 ACTIVITIES AND ACCOMPLISHMENTS

The 21st Hair Forum

The 21st Hair Forum was held on Saturday, August 19, 2023, in the Grand Ballroom of Asti Hotel Busan. In the first part, there were interesting oral presentations, and various comments and lively discussions. In the second part, there were lectures for people starting basic hair research, which provided valuable opinions to lower the barrier to entry for hair research. The third part contained the presentation of the 2023 European Hair Research Society observation report and the announcement of the 2026 World Congress for Hair Research organizing committee.



Group photo from 21st Hair Forum

The 24th Korean Dermatological Association (KDA) Education Program: 10th KHRS

On September 17, 2023, the 24th KDA Education Program: 10th KHRS was held in the Geranium Hall of Samjung Hotel in Seoul. The program is planned every two years, covers all fields of dermatology, and includes the core competencies of dermatologists. At this 10th program, the KHRS provided educational lectures on androgenetic alopecia and alopecia areata.

Symposium in the 75th KDA Autumn Meeting

The 75th Autumn meeting of the KDA was held at the Intercontinental Seoul Coex Hotel on October 21-22, 2023. On October 22, 2023, the KHRS offered a symposium for academic exchange covering the interesting topic "An Update on Female Pattern Hair Loss." The symposium featured lively discussions on the latest advances in the pathogenesis, diagnosis, and treatment of female pattern hair loss.

(Continued next page)

The 9th Continuing Hair Education Program

The 9th KHRS Continuing Hair Education Program was held on November 25, 2023, in the Laver Hall of the Samjung Hotel in Seoul. This program session discussed in depth the latest knowledge in the treatment of various hair loss disorders under the theme of “New Treatments for Various Hair Disorders.” In addition to the traditional male/female pattern hair loss and alopecia areata, the program also included lectures on seborrheic dermatitis, the most common scalp disease, hair shaft disorders, hypertrichosis/hirsutism, and trichodynia, which are rare but should not be overlooked.



2024 UPCOMING EVENTS

The Alopecia Areata Patient Association Hope Festival and General Assembly in 2024

The Alopecia Areata Patient Association Hope Festival and General Assembly will be held on January 7, 2024. The event is organized to heal and empathize with those affected by alopecia areata, and to seek and call for the support they need to live as full members of society.

The 20th Annual Meeting of the KHRS

To celebrate its 20th annual conference in 2024, the KHRS plans to invite several esteemed domestic and international notable speakers to enrich the event.

Other 2024 Events

The 22nd Hair Forum will be held in August 2024, followed by the 10th Continuing Hair Education Program in the fall of 2024.

NOTABLE RESEARCH

1. Park H, Kim JE, Choi JW, et al. **Guidelines for the management of patients with alopecia areata in Korea: Part I topical and device-based treatment & Part II systemic treatment.** *Ann Dermatol.* 2023;35(3):205-216 & 2023;35(3):190-20, respectively.
Summary: This guideline was developed by the KHRS. The study aims to provide evidence- and consensus-based insights into alopecia areata (AA) treatment in Korea. Current evidence supports the effectiveness of topical, device-based, and systemic treatments that are currently commonly implemented, with specific recommendations for pediatric patients. Despite the scarcity of robust evidence for the treatment approaches, the KHRS guidelines aim to offer up-to-date and diverse recommendations based on expert consensus in the Korean healthcare context.
2. Seok J, Cho SD, Lee J, et al. **A virtual memory CD8⁺ T cell-originated subset causes alopecia areata through innate-like cytotoxicity.** *Nat Immunol.* 2023;24(8):1308-1317.
Summary: The paper identifies CD44^{super-high(s-hi)} CD49dlo CD8⁺ T cell subset derived from virtual memory T (T_{VM}) cells as pathogenic effectors in AA. These tissue-resident cells, distinct from conventional TVM cells, induce AA through NKG2D-dependent innate-like cytotoxicity. IL-12, IL-15, and IL-18 stimulation can transform conventional T_{VM} cells into the pathogenic T cells. This study provides insights into an immunological mechanism by which T_{VM} cells contribute to chronic inflammatory diseases, specifically through innate-like cytotoxicity in AA.
3. Lee S, Ohn J, Mi Kang B, Tommy Hwang S, Kwon O. **Activation of mitochondrial aldehyde dehydrogenase 2 promotes hair growth in human hair follicles.** *J Adv Res.* Published online November 14, 2023.
Summary: This study explores the impact of activating mitochondrial aldehyde dehydrogenase 2 (ALDH2) on human hair follicles (HFs) and hair growth. ALDH2 exhibits higher intensity during the anagen phase, primarily located along the

(Continued next page)

outer layer of HFs. Activating ALDH2 promotes anagen phase induction by reducing reactive oxygen species (ROS) levels and enhancing reactive aldehyde clearance, acting as a ROS scavenger within HFs. ALDH2 activation also upregulates β -catenin signaling in HFs, suggesting its potential as a therapeutic approach for promoting anagen induction and hair growth.

4. Lim SH, Ju HJ, Han JH, et al. **Autoimmune and autoinflammatory connective tissue disorders following COVID-19.** *JAMA New Open.* 2023;6(10):e2336120. Published 2023 Oct 2.

Summary: This study investigates autoimmune and autoinflammatory connective tissue disorders following COVID-19. Utilizing data from the Korea Disease Control and Prevention Agency COVID-19 National Health Insurance Service cohort, the analysis covers the period from October 8, 2020, to December 31, 2021. Among 354,527 individuals with COVID-19 and 6,134,940 controls, elevated risks of conditions like alopecia areata, alopecia totalis, vasculitis, Crohn's disease, and sarcoidosis were observed in the COVID-19 group. Severity of COVID-19 correlated with increased risks of various connective tissue disorders. The findings highlight a substantial risk for these disorders post-COVID-19, emphasizing the importance of long-term evaluation and management in affected individuals.

5. Jang YN, Seok J, Park AY, et al. **A comparison of dyeing efficacy between hair-oxidation-based and hair-coating-based shampoos for the treatment of gray hair.** *Skin Res Technol.* 2023;29(6):e13383.

Summary: This study compares the dyeing efficacy of two types of hair color shampoos, one based on oxidation and the other on coating, aiming to understand their effects on hair. The hair-coating-based shampoo enhances dyeing effect and roughness, while the hair-oxidation-based shampoo improves color retention and moisture content. Despite similar frictional resistance, gloss, and elasticity, the hair-oxidation-based shampoo shows longer dyeing retention but may cause cuticle damage. The findings suggest that the choice between the two shampoos should be based on individual requirements, considering their distinct dyeing abilities and impact on hair health.

LOOKING AHEAD

The WCHR 2026 Organizing Committee (OC) was set up. The three co-chairs are Chang-Hun Huh, Ohsang Kwon, and Moon Bum Kim. The Congress Secretary is Bark-Lynn Lew. Yang Won Lee takes the responsibility of Scientific Program Director and Sang-Seok Kim becomes the Treasurer. The faculty of KHRS will be the OC members and we will do our best to prepare WCHR 2026 in Seoul.

14th WCHR 2026



The Korean Hair Research Society

Three Co-Chairs



Chang-Hun Huh



Ohsang Kwon



Moon-Bum Kim

Secretary General



Bark-Lynn Lew

Scientific Director



Yang-Won Lee

Treasurer



Sang-Seok Kim

Key faculty of WCHR 2026/Organizing Committee

Tatiana Silyuk, MD, RHRS Immediate Past President | tatianasiliuk@gmail.com | <https://rhirs.pro/>
Corresponding author: Andrey Panteleyev, PhD | a.a.pantel@gmail.com

Summing up the results of our work in the second half of the 2023, we can proudly conclude that all scientific and educational activities planned by the RHRS for this period of the year have been successfully realized. Specifically, we have conducted the following:

- Two webinars: “Alopecia Areata Update 2023” with 129 participants from 57 cities and “World Trichology News” with 119 participants from five countries (Russia, Uzbekistan, Belarus, Moldova, and Kazakhstan).
- A two-day in-person training course on the topic of “alopecia areata” with 18 participants from Russia and Kazakhstan (September 2023, Saint Petersburg). This event was held in a warm and friendly atmosphere, coupled with effective teaching and deep professional interest of the audience.



Attendees of the two-day training course on alopecia areata.



- The final in-person event of 2023 included a gala dinner for RHRS members (December 13th) followed by a one-day conference (December 14th) entitled, “One Day of Power–Interfollicular Focus.” Both events had over 160 participants from Russia, Cyprus, Moldova, Kazakhstan, Uzbekistan, and Belarus. The international part of the program also comprised a number of online talks given by Antonella Tosti (USA), Isabella Doche (Brazil) and Daniel Fernandes Melo (Brazil).



The final event for 2023 was held in person.



In addition, during the second half of 2023, members of the RHRS from different cities (mainly from Saint Petersburg, Moscow, and Izhevsk) took part in several international events overseas focused on hair biology and clinics. In particular, it is worth mentioning the meeting of the European Hair Research Society in Sheffield (UK) and the annual World Congress of the ISHRS in India.

The basic studies conducted by the members of the RHRS were mainly focused on hair follicle bioengineering and molecular control of the hair cycle. In particular, the research group in the Institute of Developmental Biology (RAS) has successfully trans-differentiated hiPSCs into neural progenitor cells and subsequently into dermal papilla-like cells. Analysis of bulk RNA-seq data has revealed gene expression dynamics during this process. The work of the research group at the NRC Kurchatov Institute has exposed the role of bHLH PAS transcription factors in control of cell state transitions during defined stages of the hair follicle cycling. This sheds a new light on the links between follicle cell physiology and cell fate determination.

Thus, taking into account the first half of the year, over the entire 2023, the RHRS has organized and successfully conducted 4 on-line events and held 6 in-person meetings with high attendance and significant professional outcome. This activity is one of the reasons for the continuing growth of the RHRS. Currently, we have 373 active members with a few dozen hair professionals joining the RHRS in 2023.

We are thankful to our friends and colleagues from all over the world for their support and valuable contribution to the overall success of the Russian Society for Hair Research in 2023!

Happy New Year and our best wishes for your personal and professional life!



Happy holidays from the RHRS!



The Society for Hair Science Research (Japan)

Manabu Ohyama, MD, PhD, SHSR President | manabuohy@ks.kyorin-u.ac.jp | <http://www.shsr.jp/>

REVIVAL OF IN-PERSON MEETINGS AND RECOGNITION OF DR. RYOTA HAYASHI

The influence of COVID pandemic on social activities has finally become minimal in Japan and in-person meetings revived. The SHSR members restarted to show their presence in the field of Dermatology and basic skin research. One good example is Dr. Ryota Hayashi (Assistant Professor at the Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences; Figure 1), who won the Japanese Society for Investigative Dermatology (JSID) Young Investigator Award by. Though this “rising star” award is highly competitive, the SHSR boasts consecutive receipt by our membership (last year’s winner was Dr. Misaki Kinoshita-Ise (Senior Assistant Professor at the Department of Dermatology, Kyorin University Faculty of Medicine). The award ceremony usually takes place during the annual meeting of the JSID, however, as a JSID annual meeting was replaced by the 1st International Society for Investigative Dermatology meeting this year, the ceremony took place during the 87th Annual Meeting of the Tokyo Division of the Japanese Dermatological Association (JDA), which was held November 18-19 at the Keio Plaza Hotel, Shinjuku, Tokyo. Dr. Ryota Hayashi had been supervised by Prof. Yutaka Shimomura (Professor and Chair, Department of Dermatology, Yamaguchi University Graduate School of Medicine and the Secretary General of the SHSR) for his PhD training. His achievements were mostly made in the field of genetic hair diseases, an area with a comparatively small number of researchers actively investigating it. As he was trained by Prof. Angela Christiano (Professor, Department of Dermatology and Genetics and Development, Columbia University School of Medicine, New York, USA) as a postdoctoral fellow, the award can be regarded as a nice example of international collaboration between the American Hair Research Society and the SHSR. Also at the JDA meeting, this author (Professor and Chair, Department of Dermatology, Kyorin University Faculty of Medicine) and Prof. Taisuke Ito (Clinical Professor, Department of Dermatology, Hamamatsu Medical University), respectively, gave lectures on scarring alopecia and alopecia areata.



Figure 1. Dr. Ryota Hayashi (left) won the JSID Young Investigator Award, which was presented by the JSID president, Prof. Manabu Fujimoto (Osaka Univ.; right)

SHSR 31ST ANNUAL MEETING

The SHSR annual meeting represents the most important event for the SHSR. This year, the 31st SHSR annual meeting was held under the presidency of Prof. Yasuyuki Amoh (Professor and Chair, Department of Dermatology, Kitasato University School of Medicine) at the Sankei Plaza, located near the Tokyo central station (the place where previous SHSR meetings have been held). Thanks to diligent preparation by Prof. Amoh and his colleagues, the meeting was well-organized, consisting of a well-balanced mix of basic science and clinical presentations, and it attracted good number of attendees (Figure 2). In its attempt to enhance international exchange and collaboration, the SHSR has been hosting the Korean Hair Research Society (KHRS) in the SHSR Friendship Seminar series, in which two representatives (a rising star and an



Figure 2. Attendees actively participated and exchanged opinions at the 31st SHSR meeting.

(Continued next page)



Figure 3. Prof. Byung In Ro gave a lecture on his experience with growth factor cocktail solution via microneedling for androgenetic alopecia.



Figure 4. Prof. Jung Eun Kim spoke on her research using hematopoietic stem cells for the treatment of severe alopecia areata.



Figure 5. The SHSR board of directors (left to right): Dr. Kishimoto, Dr. Kurata, Dr. Sato, Prof. Amoh, this author, Prof. Shimomura, Dr. Saito, Prof. Harada, Prof. Ueki, Dr. Kinoshita-Ise and Prof. Ito



Figure 6. At the social event (left to right): Prof. Tsuboi (former SHSR president), Prof. Shimomura, this author, Prof. Ogawa (founder of the SHSR), Prof. Ro, Prof. Kim and Prof. Amoh (president of this SHSR meeting)

established lecturer) from the KHRS and SHSR give lectures on topics of their expertise. This Friendship Seminar series provides a solid platform to establish a firm network between the KHRS and SHSR that can be extended to other hair research societies, not limited to the IFHRS societies.

For this year, on behalf of the KRHS, Prof. Byung In Ro (Invited Professor, Department of Dermatology, Myongji Hospital, Hanyang University College of Medicine; Figure 3) and Prof. Jung Eun Kim (Professor, Department of Dermatology, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea; Figure 4) gave excellent lectures, respectively, on microneedling delivery of growth factors for male/female pattern hair loss and hematopoietic stem cell transplantation therapy for alopecia areata. From the SHSR, Dr. Koya Obara (Senior Assistant Professor, Department of Dermatology, Kitasato University School of Medicine) and our secretary general, Prof. Yutaka Shimomura, gave lectures on the promise of regenerative medicine using hair-follicle-associated-pluripotent (HAP) stem cells and personal journey to dissect the pathophysiology and develop a strategy to develop remedies for inherited hair loss, especially focusing on autosomal recessive woolly hair/hypotrichosis, respectively. Each lecture was of high scientific quality and attracted great interest of the audience.

The SHSR board of directors meeting (Figure 5) and general assembly were held during the meeting, followed by special lectures by Prof. Rodney Sinclair (Sinclair Dermatology, University of Melbourne) on alopecia areata and Prof. Kazutoshi Harada (Professor and Chair, Department of Dermatology, Tokyo Medical University) and Dr. Masashi Ogo (Regenerative Medicine Research & Business, Development Department, Shiseido Co.) on their regenerative medicine project using hair follicle dermal sheath cup cells for male and female pattern hair loss.

Thanks to Prof. Amoh and his colleagues, and also to the moderation of COVID restrictions, attendees enjoyed a wonderful social event (Figure 6). At the beginning, Prof. Hideoki Ogawa (CEO, Juntendo University), the founder of the SHSR, gave an opening address and introduced a brief history of the SHSR, which was truly impressive.

ESTABLISHING BARICITINIB AND RITLECITINIB GUIDELINES

Both baricitinib and ritlecitinib have become available for the treatment of severe alopecia areata in Japan. In collaboration with the JDA, SHSR representatives are contributing to the preparation and distribution of safe use instructions. A renewal of the JDA alopecia areata management guideline is also being led by the SHSR/JDA members. Via aforementioned activities, the SHSR will endeavor to set up new standards for better management of hair loss disorders and engage in deeper dissection of hair follicle biology.

UHRS Ukrainian Hair Research Society

Yuliya S. Ovcharenko, MD, PhD, UHRS President | julya.ovcharenko@gmail.com | <https://uhrs.org.ua>

Dear colleagues, summing up the difficult year 2023, we want to express the main words of gratitude from the Ukrainian Hair Research Society (UHRS) to the Ukrainian Defense Forces for continuing to hold the first front line for freedom and calling on the entire free world to be more decisive to stop the enemy in the greatest wave of aggression and prevent the emergence of other fronts. We bow to the heroism of Ukrainian soldiers and thank them for the happiness of living and continuing our scientific and educational projects.

INTERNATIONAL RESEARCH

Following the global trend of implementing new effective therapeutic strategies in the treatment of hair diseases based on evidence-based medicine, in 2024, the UHRS joined two clinical research projects:

1. Global Consensus Initiative on Initiation and Monitoring of Low Dose Oral Minoxidil (LDM) for Hair Loss (Delphi), initiated by a University of California panel
2. European expert consensus statement on the systemic treatment of alopecia areata, under the leadership of Polish colleagues, who united leading experts in forming a consensus opinion in determining the algorithm for systemic treatment of alopecia areata, indications for systemic treatment, available treatment options and their effectiveness and safety, as well as duration of therapy.

UHRS SUMMIT 2023

Today, at the dawn of the era of JAK inhibitors, in line with the world scientific trends in trichology, we held the UHRS winter summit, "Janus-kinase Inhibitors in the Practice of the Clinician," with the support of Pfizer (<https://www.uhrs-education.com/>). The discovery of cytokines and their role in immune and inflammatory diseases led to the development of many targeted biological methods of treatment. Later, efforts to understand the mechanisms of cytokine signal transmission led to the discovery of JAKs, which themselves were identified as therapeutic targets. A little more than 10 years have passed since the first JAK inhibitors were approved, and currently there are 10 jakinib drugs approved for the treatment of several diseases, including trichological pathologies. We summarized the relevant discoveries that led to the creation of the first-generation jakinibs, discussed the clinical success of jakinibs based on their effectiveness and safety demonstrated in major clinical studies, and finally, we discussed both the possibilities and the upcoming debatable issues when we enter in the second decade of clinical use of jakinibs.



(l to r) Prof. Yuliya Ovcharenko (President of UHRS), Dr. Kuzma Khobzey (General Secretary of UHRS), Prof. Inessa Serbina (Treasurer of UHRS) on the recording of the UHRS Summit 2023 "Janus-Kinase Inhibitors in the Practice of the Clinician" for the translation via the new educational platform for continuous medical education in trichology: UHRS EDUCATION.

(Continued next page)

UHRS EDUCATION PLATFORM

UHRS Summit 2023, dedicated to the implementation of Janus kinase inhibitors in clinical practice, was broadcast on the UHRS education platform <https://www.uhrs-education.com/>. This global hybrid educational platform for continuing medical education in the field of dermatotrichology was created jointly by experts, researchers, dermatologists and trichologists, and leading laboratories and universities based on advanced scientific research, their own experience, and data from professional congresses. This progressive project, launched in the summer of 2023, currently unites more than 650 Ukrainian-speaking users. For third-party visitors, the platform has an incognito Terra: most sections are closed, but they are actively updated with high-quality original content, including the English version of the resource. Starting January 2024, the platform will have annual subscription options, and we are preparing an incredibly rich learning year with certification points for our members. We will be happy to invite colleagues from all over the world to exchange experiences on the UHRS educational platform in the near future.

IMPLEMENTATION OF GOOD CLINICAL PRACTICE

Along with fundamental research on other targeted molecules, we expect the launch of Ritlecitinib in Ukraine in 2025, which is a significant prerequisite for reviewing the UHRS recommendations for the management of patients with alopecia areata (AA) in 2025, which we are already working on today. Carefully analyzing international and our own clinical experience in integrating JAK inhibitors into AA treatment algorithms, we continue to work on creating an all-Ukrainian registry of patients with AA. This registry is a new form of collaboration and interaction between patients, doctors, and researchers. Providing comprehensive patient care requires insight and understanding of all aspects of the disease. The registry will provide the opportunity for a retrospective analysis of patients to study the course of the disease and the effectiveness of existing treatment methods, as well as the opportunity to expand the geographical area of research and include Ukrainian patients in special programs for new treatment methods for AA. Especially considering there is an increased need for effective treatment of AA in Ukraine, now more than ever. According to preliminary statistics from specialized dermatotrichological clinics in Ukraine, we are seeing an increase in the incidence of five nosologies among military personnel and civilians in the combat zone compared to the previous pre-war year, among which is alopecia areata, which is showing an increase in incidence of 8.2%.

FUTURE NATIONAL SCIENTIFIC CONGRESSES

For many years, we have been uniting science and practice, doctors and patients, and experts and young specialists, leading scientific associations to create friendly professional connections and integrate and relay the world trichological knowledge. But today our main task is to support each other and do everything for a speedy victory. During the magical New Year period, January 26-27, 2024, in Kyiv—the heart of our country—we will open the new educational season by holding a charitable scientific event: the 4th UHRS Congress 2024. The New Year is exactly the time to touch every heart with love and care. Therefore, the scientific component of the congress will be devoted to one of the most difficult topics—cicatricial alopecia. Recognized world experts will be the invited top speakers of the event and include Professor Bianca Maria Piracini (Italy), Dr. Daniel Asz Sigall (Mexico), Dr. Maryanne Makredes Senna (USA), Professor Maria Fernanda Gavazzoni (Brazil), Professor Nino Lortkipanidze (Georgia), Dr. Anna Lyakhovitsky (Israel), Dr. Daniel Fernandes Melo (Brazil).

A powerful, relevant component of the 4th UHRS Congress 2024 will be a unique interactive session dedicated to the correlations of clinical, trichoscopic, and pathohistological pictures of cicatricial alopecia. Among the newest areas of hair research, the results of original Ukrainian studies on the use of quantitative trichoscopy based on mathematical modeling will be presented to optimize planning and evaluate the effectiveness of autologous hair transplantation in patients with androgenetic alopecia. Already traditional in the UHRS scientific event program for young clinicians, an interactive clinical and trichological quiz will be offered. And we will be happy to award useful prizes and travel grants for international hair research events to the winners of the competition. The money collected from the tickets sold will be transferred to support military doctors—our colleagues at the front. We must remember every day: at what heavy cost we are approaching victory and support our colleagues saving the soldiers!

One step away from the peace, we maintain the level of the highest quality congress and continue to write the history of Ukrainian trichology. On behalf of UHRS members, we would like to express gratitude to everyone who is helping to bring our victory closer: colleagues, public leaders, and people of different countries who believe in Ukraine. We thank all the indestructible Ukrainians who, week after week, prove to the world by their own example that Ukraine will stand, maintain its independence, and win.

Happy New Year, Year of Victory!

2026 AND BEYOND

The following dates and locations have been decided on by the IFHRS:

2026

14th WCHR

May 28-31, 2026

Venue: North Wing of COEX

Seoul, Korea

Co-chairs Chang-Hun Huh, Ohsang

Kwon, & Moon-Bum Kim

Hosting Society: KHRS

www.hair2026.org

2028

15th WCHR

Europe

Hosting Society: EHRS, RHRS, or UHRS

2030

16th WCHR

Open Hub

Hosting Society: TBD

Staff and Member Societies

Chair: Wilma F. Bergfeld, MD

Executive Secretary: Victoria Ceh, MPA

Immediate Past Chair: Gillian Westgate, PhD

Managing Editor, IFHRS Newsletter: Cheryl Duckler

IFHRS MEMBER SOCIETIES

American Hair Research Society – founding member

Australasian Hair and Wool Research Society – founding member

Chinese Hair Research Society

European Hair Research Society – founding member

The Korean Hair Research Society – founding member

Russian Hair Research Society

The Society for Hair Science Research – founding member

Ukrainian Hair Research Society

© IFHRS, c/o AHRs, 1932 S. Halsted St., Suite 413, Chicago, IL 60608, USA